Sinocare Inc (300298) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Sinocare Inc (300298) has a cash flow conversion efficiency ratio of 0.072x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥264.19 Million ≈ $38.66 Million USD) by net assets (CN¥3.67 Billion ≈ $537.71 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Sinocare Inc defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Sinocare Inc - Cash Flow Conversion Efficiency Trend (2008–2024)
This chart illustrates how Sinocare Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Sinocare Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sinocare Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Beijing Jingyuntong Technology Co Ltd
SHG:601908
|
0.051x |
|
Shenzhen Das Intellitech Co Ltd
SHE:002421
|
-0.038x |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
|
0.014x |
|
Catalyst Metals Ltd
AU:CYL
|
0.205x |
|
Huadian Heavy Industries Co
SHG:601226
|
-0.055x |
|
Advantage Oil & Gas Ltd.
TO:AAV
|
0.048x |
|
Vulcan Energy Resources Limited
AU:VUL
|
-0.049x |
|
Financial Street Holdings Co Ltd
SHE:000402
|
0.018x |
Annual Cash Flow Conversion Efficiency for Sinocare Inc (2008–2024)
The table below shows the annual cash flow conversion efficiency of Sinocare Inc from 2008 to 2024. For the full company profile with market capitalisation and key ratios, see 300298 market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥3.77 Billion ≈ $551.61 Million |
CN¥631.29 Million ≈ $92.38 Million |
0.167x | -20.94% |
| 2023-12-31 | CN¥3.47 Billion ≈ $507.88 Million |
CN¥735.15 Million ≈ $107.57 Million |
0.212x | +40.36% |
| 2022-12-31 | CN¥3.14 Billion ≈ $460.00 Million |
CN¥474.39 Million ≈ $69.42 Million |
0.151x | -12.21% |
| 2021-12-31 | CN¥2.79 Billion ≈ $408.61 Million |
CN¥480.03 Million ≈ $70.24 Million |
0.172x | -6.63% |
| 2020-12-31 | CN¥2.74 Billion ≈ $401.11 Million |
CN¥504.64 Million ≈ $73.84 Million |
0.184x | -6.72% |
| 2019-12-31 | CN¥2.65 Billion ≈ $387.62 Million |
CN¥522.81 Million ≈ $76.50 Million |
0.197x | +62.15% |
| 2018-12-31 | CN¥2.62 Billion ≈ $383.83 Million |
CN¥319.27 Million ≈ $46.72 Million |
0.122x | -30.65% |
| 2017-12-31 | CN¥1.39 Billion ≈ $203.34 Million |
CN¥243.89 Million ≈ $35.69 Million |
0.176x | +10.25% |
| 2016-12-31 | CN¥1.28 Billion ≈ $186.99 Million |
CN¥203.42 Million ≈ $29.77 Million |
0.159x | +62.46% |
| 2015-12-31 | CN¥1.24 Billion ≈ $181.47 Million |
CN¥121.52 Million ≈ $17.78 Million |
0.098x | -28.90% |
| 2014-12-31 | CN¥1.11 Billion ≈ $162.61 Million |
CN¥153.15 Million ≈ $22.41 Million |
0.138x | +13.95% |
| 2013-12-31 | CN¥946.01 Million ≈ $138.43 Million |
CN¥114.42 Million ≈ $16.74 Million |
0.121x | -20.83% |
| 2012-12-31 | CN¥845.18 Million ≈ $123.68 Million |
CN¥129.12 Million ≈ $18.89 Million |
0.153x | -68.09% |
| 2011-12-31 | CN¥179.51 Million ≈ $26.27 Million |
CN¥85.93 Million ≈ $12.57 Million |
0.479x | -34.81% |
| 2010-12-31 | CN¥91.35 Million ≈ $13.37 Million |
CN¥67.08 Million ≈ $9.82 Million |
0.734x | -29.18% |
| 2009-12-31 | CN¥41.49 Million ≈ $6.07 Million |
CN¥43.03 Million ≈ $6.30 Million |
1.037x | +136.80% |
| 2008-12-31 | CN¥17.42 Million ≈ $2.55 Million |
CN¥7.63 Million ≈ $1.12 Million |
0.438x | -- |
About Sinocare Inc
Sinocare Inc. engages in the development, manufacture, and marketing of rapid diagnosis testing products primarily in the People's Republic of China. It offers blood glucose and pressure monitors; point of care testing products; digital management tool solutions; non-invasive screening products; and PTS and Trividia products. The company provides its products for the patients with chronic disease… Read more